Kamada Ltd. (NASDAQ:KMDA - Get Free Report)'s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.46 and traded as low as $5.06. Kamada shares last traded at $5.10, with a volume of 7,991 shares changing hands.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on KMDA shares. HC Wainwright reissued a "buy" rating and set a $11.00 price objective on shares of Kamada in a research report on Thursday, March 7th. StockNews.com raised shares of Kamada from a "hold" rating to a "buy" rating in a research report on Thursday, January 4th.
Read Our Latest Research Report on KMDA
Kamada Stock Performance
The stock's 50-day moving average price is $5.72 and its two-hundred day moving average price is $5.46. The stock has a market capitalization of $293.10 million, a PE ratio of 34.00 and a beta of 1.04.
Kamada (NASDAQ:KMDA - Get Free Report) last released its earnings results on Wednesday, March 6th. The biotechnology company reported $0.09 earnings per share for the quarter, topping analysts' consensus estimates of $0.05 by $0.04. The firm had revenue of $36.43 million for the quarter, compared to the consensus estimate of $37.71 million. Kamada had a net margin of 5.81% and a return on equity of 5.66%. On average, analysts predict that Kamada Ltd. will post 0.23 earnings per share for the current fiscal year.
Institutional Trading of Kamada
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Meitav Investment House Ltd. grew its position in Kamada by 17.2% during the 3rd quarter. Meitav Investment House Ltd. now owns 76,835 shares of the biotechnology company's stock valued at $412,000 after purchasing an additional 11,284 shares during the last quarter. Y.D. More Investments Ltd bought a new stake in shares of Kamada during the third quarter valued at approximately $75,000. Aristides Capital LLC lifted its position in Kamada by 41.6% in the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company's stock valued at $347,000 after acquiring an additional 16,635 shares in the last quarter. Calton & Associates Inc. bought a new stake in shares of Kamada in the 4th quarter worth $111,000. Finally, EWA LLC purchased a new position in shares of Kamada in the fourth quarter worth $68,000. 20.38% of the stock is owned by hedge funds and other institutional investors.
Kamada Company Profile
(
Get Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
See Also
Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
